HIK Insider Trading

Insider Ownership Percentage: 17.77%
Insider Buying (Last 12 Months): £10,925,125.58
Insider Selling (Last 12 Months): £346,376.94

Hikma Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Hikma Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Hikma Pharmaceuticals Share Price & Price History

Current Price: GBX 1,595
Price Change: Price Increase of +5 (0.31%)
As of 12/5/2025 05:34 AM ET

This chart shows the closing price history over time for HIK up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Hikma Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/7/2025Said DarwazahInsiderBuy70,000GBX 1,541£1,078,700
11/7/2025Said DarwazahInsiderBuy60,000GBX 1,589£953,400
11/7/2025Victoria HullInsiderBuy3,214GBX 1,547£49,720.58
11/6/2025Mazen DarwazahInsiderBuy315,000GBX 1,601£5,043,150
9/16/2025Mazen DarwazahInsiderBuy14,000GBX 1,603£224,420
8/22/2025Laura Balan BalanInsiderBuy3,500GBX 1,821£63,735
8/7/2025Mazen DarwazahInsiderBuy200,000GBX 1,756£3,512,000
5/30/2025Said DarwazahInsiderSell13,863GBX 2,138£296,390.94
4/8/2025Victoria HullInsiderSell2,777GBX 1,800£49,986
5/7/2024Riad MishlawiInsiderBuy736GBX 1,979£14,565.44
6/6/2023Douglas HurtInsiderBuy1,500GBX 1,820£27,300
1/17/2023Deneen VojtaInsiderBuy1,000GBX 1,703£17,030
See Full Table

SEC Filings (Institutional Ownership Changes) for Hikma Pharmaceuticals (LON:HIK)

63.62% of Hikma Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Hikma Pharmaceuticals logo
At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing facilities, 9 R&D centres and 9,500 employees worldwide.
Read More on Hikma Pharmaceuticals

Today's Range

Now: GBX 1,595
Low: 1,588
High: 1,597

50 Day Range

MA: GBX 1,698.95
Low: 1,522
High: 1,851

52 Week Range

Now: GBX 1,595
Low: 1,522
High: 2,360

Volume

373,800 shs

Average Volume

1,909,390 shs

Market Capitalization

£3.53 billion

P/E Ratio

9.55

Dividend Yield

4.09%

Beta

0.41

Who are the company insiders with the largest holdings of Hikma Pharmaceuticals?

Hikma Pharmaceuticals' top insider shareholders include:
  1. Laura Balan Balan (Insider)
  2. Mazen Darwazah (Insider)
  3. Riad Mishlawi (Insider)
  4. Said Darwazah (Insider)
  5. Victoria Hull (Insider)
Learn More about top insider investors at Hikma Pharmaceuticals.